Changes in Beneficial Ownership · 4
Legend Biotech Corp
Changes in Beneficial Ownership
Structured filing — 4
form4-09282026_040901.xml
Filing details
- Report period
- 2026-09-24
- Issuer
- Legend Biotech Corp
- Issuer CIK
- 0001801198
- Trading symbol
- LEGN
Reporting owner 1
- Name
- Sanders Corazon (Corsee) D.
- Reporting owner CIK
- 0001796536
- Relationship
- Director
- Address
- C/O LEGEND BIOTECH CORP, 77 CORPORATE DRIVE, 4TH FLOOR, BRIDGEWATER, NJ, 08807
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Ordinary Shares[F1] | 2026-09-24 | A · Form 4 | 20,986[F2] | A | 0 | 80,101 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.↩ 1
- F2
- Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder of the RSUs vesting in 12 equal quarterly installments beginning on March 20, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Robert Staloff, Attorney-in-Fact
- Date
- 2026-09-28
Company context
With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.